Zeus Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 18 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.83 M
- Satisfied Charges ₹ 1.50 M
- Revenue Growth 0.60%
- Profit Growth 1.36%
- Ebitda 59.14%
- Net Worth 4.24%
- Total Assets -2.30%
About Zeus Drugs
Zeus Drugs Limited (ZDL) is a Public Limited Indian Non-Government Company incorporated in India on 31 August 2006 and has a history of 18 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹8.83 M. The company has closed loans amounting to ₹1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rajiv Sharma, Rajendra Sharma, and Ritu Sharma serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85121DL2006PLC152815
-
Company No.
152815
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
31 Aug 2006
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Zeus Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Sharma
|
Director | 04-Sep-2006 | Current |
|
Rajendra Sharma
|
Director | 31-Aug-2006 | Current |
| Ritu Sharma | Director | 21-Feb-2024 | Current |
Financial Performance of Zeus Drugs.
Zeus Drugs Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.6% increase. The company also saw a slight improvement in profitability, with a 1.36% increase in profit. The company's net worth moved up by a moderate rise of 4.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeus Drugs?
In 2023, Zeus Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹8.83 M
₹1.50 M
Charges Breakdown by Lending Institutions
- Others : 0.88 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Aug 2024 | Others | ₹4.13 M | Open |
| 07 Apr 2014 | Others | ₹4.70 M | Open |
| 18 Sep 2008 | Punjab National Bank | ₹1.50 M | Satisfied |
How Many Employees Work at Zeus Drugs?
Zeus Drugs has a workforce of 4 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeus Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
